PubMed Health⌕ Search

Biomedical subjects

M W Dysken

Publications and source records attributed to M W Dysken.

At least 55 records · Page 3Linked to original sources
PubMed1983

Urinary MHPG and ward behavior in unmedicated psychiatric patients.

The relationship between urinary excretion of 3-methoxy-4-hydroxyphenylglycol (MHPG) and overt behaviors emitted in two hospital environments was examined in a group of 27 drug-free psychiatric patients. Depressed patients with high MHPG excretion ate less and engaged in less visual activity in the lunch environment. Schizophrenic patients but not depressive patients with high MHPG tended to have greater body activity during the gym environment. The implications of these findings for the identification of subtypes of depression and schizophrenia, and for an improved methodology in investigation of biobehavioral relations in clinical populations, are discussed.

Adult↗
PubMed1983

Effect of lecithin on memory in normal adults.

In a double-blind, placebo-controlled, crossover study of the effect of lecithin on memory test performance, nine normal paid volunteers (age range = 22-55 years) took single oral doses of placebo and lecithin (20 g) 5 hours before cognitive testing. Lecithin raised plasma choline levels during the test session to nearly double the placebo levels, but a categorized serial learning task, a word recognition task, a paired associates learning task, and a test of retrieval by category demonstrated no significant change in memory performance. Lecithin did not selectively enhance memory for low-imagery words. Lecithin also had no effect on psychomotor speed.

Adult↗
PubMed1981

Fluphenazine pharmacokinetics and therapeutic response.

We conducted a double-blind study of therapeutic outcome versus mean steady-state levels in 29 newly admitted schizophrenic and schizoaffective patients who were treated with a constant dose of fluphenazine HCI over a 2-week period. both an upper and lower end of the therapeutic window were suggested by three nonresponders whose plasma levels were above 2.8 ng per ml and by two nonresponders and one partial responder whose plasma levels were below 0.2 ng per ml. The mean terminal half-life of fluphenazine (+ or - SD) was 16.4 + or - 13.3 h. We found that concomitant use of benztropn mesylate during the initial 4 weeks of fluphenazine treatment did not significantly alter fluphenazine plasma levels.

Acetylation↗
PubMed1979

Clinical usefulness of sodium amobarbital interviewing.

We report a double-blind, randomized, placebo-controlled study utilizing a within-subjects design on 20 hospitalized, psychiatric patients who participated in sodium amobarbital interviews to determine if the drug has a specific effect in eliciting clinically useful information. The patients selected had difficulty communicating with their primary therapists during the postadmission, diagnostic interviews. Two raters completed a Hamilton Depression Scale, a New Haven Schizophrenia Index, and a Brief Psychiatric Rating Scale after each interview. Although both the amobarbital and saline interviews were moderately useful in obtaining new information, we found no significant difference in the primary therapists' assessments of clinical usefulness. In addition, the drug interview did not uncover material that would aid in the differential diagnosis between depression and schizophrenia. There was, however, a significant negative correlation between the assessment of general usefulness and the time interval between admission and interviewing. We report our only exception, a case of catatonic schizophrenia, in which the patient responded specifically to the drug.

Adult↗